MCID: HPT004
MIFTS: 43

Hepatic Coma

Categories: Liver diseases, Neuronal diseases

Aliases & Classifications for Hepatic Coma

MalaCards integrated aliases for Hepatic Coma:

Name: Hepatic Coma 12 54 15 70
Hepatic Encephalopathy 44 70
Hepatocerebral Intoxication 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12550
MeSH 44 D006501
SNOMED-CT 67 197332007
ICD10 32 K72.91
UMLS 70 C0019147 C0019151

Summaries for Hepatic Coma

MalaCards based summary : Hepatic Coma, also known as hepatic encephalopathy, is related to viral hepatitis and acute liver failure. An important gene associated with Hepatic Coma is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Formation of Fibrin Clot (Clotting Cascade) and Complement and coagulation cascades. The drugs Midazolam and Propofol have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and cortex, and related phenotype is cardiovascular system.

Related Diseases for Hepatic Coma

Diseases related to Hepatic Coma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 520)
# Related Disease Score Top Affiliating Genes
1 viral hepatitis 31.7 GPT F2 ALB AFP
2 acute liver failure 30.9 TSPO GPT F2
3 hepatic encephalopathy 30.7 TSPO GPT F2 ALB
4 portal vein thrombosis 30.4 SERPINC1 F2 AFP
5 hepatorenal syndrome 30.4 GPT F2 ALB
6 intracranial hypertension 30.3 SERPINC1 F3 F2
7 cholestasis 30.2 GPT F2 ALB
8 liver disease 30.2 GPT F3 F2 ALB AFP
9 acute kidney failure 30.2 GPT F2 ALB
10 hepatitis a 30.1 GPT F3 F2 ALB AFP
11 active peptic ulcer disease 30.1 F3 F2 ALB
12 non-a-e hepatitis 30.1 F2 ALB
13 autoimmune hepatitis 30.0 GPT F2 ALB
14 schistosomiasis 30.0 GPT F2 ALB
15 portal hypertension 30.0 GPT F3 F2 ALB
16 hepatitis b 30.0 GPT F2 ALB AFP
17 acute cystitis 29.9 GPT F2 ALB
18 hepatitis e 29.9 GPT F2 ALB
19 wernicke encephalopathy 29.9 TSPO ALB
20 liver cirrhosis 29.9 SERPINC1 GPT F3 F2 ALB AFP
21 reye syndrome 29.8 GPT F2 ALB
22 alcoholic hepatitis 29.8 GPT F2 ALB
23 peliosis hepatis 29.8 GPT F2 AFP
24 eclampsia 29.8 SERPINC1 F2 ALB
25 rocky mountain spotted fever 29.8 GPT F3
26 cholecystitis 29.7 GPT F2 ALB
27 placenta praevia 29.7 NDUFA12 F2
28 kwashiorkor 29.7 GPT F2 ALB
29 respiratory failure 29.7 GPT F3 F2 ALB
30 alcoholic liver cirrhosis 29.7 GPT F2 ALB AFP
31 biliary atresia 29.7 GPT F2 ALB
32 metabolic acidosis 29.7 GPT F2 ALB
33 inherited metabolic disorder 29.6 GPT F2 ALB
34 carotid artery thrombosis 29.6 SERPINC1 F3
35 cellulitis 29.6 GPT F3 F2 ALB
36 cholangitis 29.5 GPT F3 F2 ALB
37 papilledema 29.5 SERPINC1 F3 F2 ALB
38 budd-chiari syndrome 29.4 SERPINC1 F3 F2 ALB AFP
39 antiphospholipid syndrome 29.4 SERPINC1 F3 F2
40 aspiration pneumonia 29.3 GPT F3 F2 ALB
41 exanthem 29.3 GPT F3 F2 ALB
42 pulmonary hypertension 29.3 SERPINC1 F3 F2 ALB
43 nephrotic syndrome 29.3 SERPINC1 F3 F2 ALB
44 hypersplenism 29.2 SERPINC1 GPT F2 ALB
45 disseminated intravascular coagulation 29.2 SERPINC1 GPT F3 F2
46 deficiency anemia 29.2 SERPINC1 GPT F2 ALB
47 esophageal varix 29.2 SERPINC1 GPT F3 F2 ALB AFP
48 pre-eclampsia 29.1 SERPINC1 F3 F2 ALB AFP
49 stroke, ischemic 29.1 TSPO SERPINC1 F3 F2 ALB
50 thrombocytopenia 29.0 SERPINC1 GPT F3 F2 ALB

Graphical network of the top 20 diseases related to Hepatic Coma:



Diseases related to Hepatic Coma

Symptoms & Phenotypes for Hepatic Coma

MGI Mouse Phenotypes related to Hepatic Coma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.23 ALB F2 F3 GOT1 HRH3 SCN1A

Drugs & Therapeutics for Hepatic Coma

Drugs for Hepatic Coma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
2
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
3
Metformin Approved Phase 4 657-24-9 4091 14219
4
Insulin aspart Approved Phase 4 116094-23-6 16132418
5
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
6
Propranolol Approved, Investigational Phase 4 525-66-6 4946
7
Promethazine Approved, Investigational Phase 4 60-87-7 4927
8
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
9
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
10
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 644073 40400
11
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
12
Midodrine Approved Phase 4 133163-28-7, 42794-76-3 4195
13
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
14
Ornithine Approved, Nutraceutical Phase 4 70-26-8, 3184-13-2 6262
15
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
16
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
17
Valine Approved, Nutraceutical Phase 4 72-18-4 6287
18 GABA Modulators Phase 4
19 Psychotropic Drugs Phase 4
20 Anesthetics, General Phase 4
21 Anesthetics, Intravenous Phase 4
22 Anti-Anxiety Agents Phase 4
23 Hypoglycemic Agents Phase 4
24 Neurotransmitter Agents Phase 4
25 N-Methylaspartate Phase 4
26 Vasoconstrictor Agents Phase 4
27 retinol Phase 4
28 Retinol palmitate Phase 4
29 Vasodilator Agents Phase 4
30 Anesthetics Phase 4
31 Hypnotics and Sedatives Phase 4
32 Anti-Arrhythmia Agents Phase 4
33 Adrenergic alpha-Antagonists Phase 4
34 Adrenergic alpha-1 Receptor Antagonists Phase 4
35 Adrenergic Antagonists Phase 4
36 Adrenergic Agents Phase 4
37 Antihypertensive Agents Phase 4
38 Adrenergic beta-Antagonists Phase 4
39 Hormones Phase 4
40 calcium channel blockers Phase 4
41 Calcium, Dietary Phase 4
42 Narcotics Phase 4
43 Analgesics, Opioid Phase 4
44 Analgesics Phase 4
45 Antiemetics Phase 4
46 Histamine Antagonists Phase 4
47
Histamine Phosphate Phase 4 51-74-1 65513
48 Dermatologic Agents Phase 4
49 Anesthetics, Local Phase 4
50 Histamine H1 Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 163)
# Name Status NCT ID Phase Drugs
1 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open Label, Randomized Controlled Trial of Lactulose, Probiotics and No-therapy Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
2 Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy: A Randomized Open Controlled Study Unknown status NCT03077217 Phase 4 Rifaximin
3 Randomized Trial Comparing The Efficacy of PEG (Polyethylene Glycol) Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy Unknown status NCT03100513 Phase 4 Lactulose;Polyethylene Glycol
4 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis: an Open Labeled Randomized Controlled Trial of Lactulose Versus no Lactulose Unknown status NCT01175538 Phase 4 Lactulose;Lactulose
5 Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy Unknown status NCT02401490 Phase 4 Human albumin;Placebo
6 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Liver Cirrhosis and Minimal Encephalopathy: a Single Center Placebo Control Double Blind Study Unknown status NCT00896831 Phase 4 L-ornithine-L-aspartate;placebo
7 Randomized Controlled Trial Comparing Effects of Sedation for Upper Gastrointestinal Endoscopy With Propofol Versus Midazolam on Psychometric Tests and Critical Flicker Frequency in Cirrhotics Unknown status NCT01356121 Phase 4 Propofol;Midazolam
8 Metformin Experience on Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis Unknown status NCT02470546 Phase 4 Metformin;Placebo
9 LOLA in Hepatic Encephalopathy Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate A Phase iv Randomised Double Blind Placebo- Controlled Trial Completed NCT01847651 Phase 4 LOLA or placebo
10 Effect of Albumine Infusion in the Prevention of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Completed NCT01559519 Phase 4 Albumin
11 Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life Completed NCT00375375 Phase 4 Lactulose
12 The Infusion of L-Ornithine L-aspart is as Effective as Nonabsorbable Disaccharides in the Management of Acute Hepatic Encephalopathy. Completed NCT01041755 Phase 4 L-ornithine-L-aspartate;Lactose
13 Rifaximin and Its Microbial Resistance as a Secondary Prophylaxis of Hepatic Encephalopathy in Patients With HCV Related Cirrhosis Completed NCT04736836 Phase 4 Rifaximin
14 A Multicenter, Randomized, Open-Label, Active-Controlled, Trial to Evaluate the Safety and Efficacy of Rifaximin 550 mg With and Without Lactulose in Subjects With a History of Recurrent Overt Hepatic Encephalopathy Completed NCT01842581 Phase 4 Rifaximin;Lactulose
15 Efficacy of Combined Oral L-ornithine-L-aspartate and Oral Lactulose in Patients With Hepatic Encephalopathy Completed NCT00740142 Phase 4 L-ornithine-L-aspartate and lactulose;placebo and lactulose
16 Comparison of Three Different Schemes:Lactulose, L-ornithine L-aspartate, or Rifaximin, Versus Placebo, as Primary Prophylaxis of the Development of Hepatic Encephalopathy After Acute Variceal Bleeding in Cirrhotic Patients Completed NCT02158182 Phase 4 Lactulose;L-ornithine L-aspartate;Rifaximin;Placebo
17 Effects of the Administration of Albumin in Patients With Cirrhosis and Acute Hepatic Encephalopathy. Completed NCT00886925 Phase 4 Albumin;Sodium chloride 0.9%
18 Effect of the Proteins of the Diet in Patients With Cirrhosis and a Prior Episode of Hepatic Encephalopathy. A Randomized Study Completed NCT00955500 Phase 4
19 Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
20 Pharmacokinetics of Buprenorphine and Naloxone in Subjects With Mild to Severe Hepatic Impairment (Child-Pugh Classes, A, B, and C), in HCV-Seropositive Subjects, and in Healthy Volunteers Completed NCT01846455 Phase 4 2.0mg Buprenorphine/0.5mg Naloxone;Promethazine
21 Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation Completed NCT00839358 Phase 4 albumin;Midodrine;Placebo
22 Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial Completed NCT01722578 Phase 4 L-ornithine L-aspartate;Placebo
23 A Placebo Controlled Single Centre Double Blind Randomised Trial to Investigate the Efficacy of Rifaximin Versus Placebo in Improving Systemic Inflammation and Neutrophil Malfunction in Patients With Cirrhosis and Chronic Hepatic Encephalopathy Completed NCT02019784 Phase 4 Rifaximin-α;Placebo Oral Tablet
24 Therapeutic Efficacy of Oral PEG3350 Plus Lactulose Versus Lactulose Alone in Patients of Acute on Chronic Liver Failure With Overt Hepatic Encephalopathy: A Single Blind Prospective Randomized Controlled Study Recruiting NCT03987893 Phase 4 PEG-3350 with Electolytes;Lactulose
25 Effect of Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Liver Cirrhosis; a Randomized Clinical Trial (PEGHE Trial) Recruiting NCT04436601 Phase 4 Polyethylene Glycols;Lactulose
26 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy Recruiting NCT01846663 Phase 4 Placebo;Rifaximin
27 Prevention of Hepatic Encephalopathy by Administration of Rifaximin and Lactulose in Patients With Liver Cirrhosis Undergoing TIPS Placement: a Multi-centre Randomized, Double Blind, Placebo Controlled Trial. Recruiting NCT04073290 Phase 4 Rifaximin 550 milligram Oral Tablet [XIFAXAN];Placebo oral tablet;Lactulose 667 milligram/milliliter Oral Solution
28 Effects of Intrathoracic Pressure Regulation Therapy in Patients With Elevated Intracranial Pressure Due to Brain Injury or Intracranial Pathology Terminated NCT01824589 Phase 4
29 A Multi-Center Trial to Study Acute Liver Failure: N-Acetylcysteine (NAC) Open Label Use Study Terminated NCT00896025 Phase 4 N-acetylcysteine
30 Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy Using Rifaximin. Terminated NCT01842113 Phase 4 Rifaximin;Lactulose;Lactulose Placebo;Rifaximin Placebo
31 Impact of Rifaximin on Liver Fibrosis in HIV-Infected Patients With Liver Disease Withdrawn NCT01654939 Phase 4 Rifaximin
32 Minimal Hepatic Encephalopathy in Pre-hepatic Portal Hypertension Due to Portal Vein Thrombosis in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study. Unknown status NCT01798329 Phase 3
33 Randomized Double Blind Placebo Controlled Trial of Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage Unknown status NCT00553423 Phase 3 Lactulose;Placebo
34 A Randomized, Double-blind, Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone Treatment of Overt Hepatic Encephalopathy Unknown status NCT02464124 Phase 2, Phase 3 Nitazoxanide;Lactulose
35 A Multi-center Study of the Safety and Efficacy of N-acetylcysteine in the Treatment of Acute Liver Failure in Pediatric Patients Not Caused by Acetaminophen. Completed NCT00248625 Phase 3 N-acetylcysteine;Placebo
36 13C-Methacetin Breath Test for the Prediction of Outcome in in Acute Liver Injury or Acute Liver Failure Completed NCT02786836 Phase 2, Phase 3 13C-Methacetin
37 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID For 6 Months In Preventing Hepatic Encephalopathy Completed NCT00298038 Phase 3 Rifaximin;Placebo
38 Efficacy of a Three Days' Infusion of L-Ornithine-L-Aspartate as an Adjuvant Therapy in Cirrhotic Patients With Overt Hepatic Encephalopathy: A Placebo Controlled Study Completed NCT00433368 Phase 3 L-Ornithine L-Aspartate
39 Secondary Prophylaxis of Hepatic Encephalopathy: A Double Blind, Randomized, Placebo Controlled Study With Supplementation With a Probiotic Preparation Completed NCT01110447 Phase 2, Phase 3 VSL#3
40 A Multi-Center, Open-Label Trial to Evaluate the Long-Term Safety and Tolerability of Rifaximin 550 mg BID in Subjects With a History of Hepatic Encephalopathy Completed NCT00686920 Phase 3 Rifaximin
41 Health Related Quality of Life in Patient With Chronic Liver Disease and Effect of Probiotics in the Treatment of MHE and Health Related Quality of Life Completed NCT01008293 Phase 2, Phase 3 VSL#3;Lactulose
42 Effects of Tolvaptan on Cognitive Function, Brain Metabolism and Quality of Life in Hyponatremic Cirrhotics With Hepatic Encephalopathy: A Prospective Clinical Trial Completed NCT01556646 Phase 3 Tolvaptan
43 Acetyl-L-Carnitine Reduces Perceived Work Stress and Improves Work Ability and Work Performance in Hepatic Encephalopathy Completed NCT02173132 Phase 3 Acetyl-L-carnitine
44 Clinical Study Evaluating the Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy Recruiting NCT04161053 Phase 3 Rifaximin;Nitazoxanide
45 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of MNK6105 (an Intravenous Formulation of L-Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Hyperammonemia Associated With an Episode of Hepatic Encephalopathy Not yet recruiting NCT04128462 Phase 3 MNK-6105;Placebo;Standard of Care
46 Evaluation of the Therapeutic Effect of Rifaximin on Covert Hepatic Encephalopathy With Underlying Small Intestinal Bacterial Overgrowth and Gastrointestinal Dysmotility in Liver Cirrhosis Patients Not yet recruiting NCT04244877 Phase 3 Rifaximin
47 A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD® in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure Terminated NCT01829347 Phase 3
48 RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial Terminated NCT00364689 Phase 3 Rifaximin;Lactulose
49 A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure Withdrawn NCT02086825 Phase 3 Rifaximin;Lactulose
50 The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy. Phase A: Breath Testing and Colonic Transit in Hepatic Encephalopathy. Phase B: A Randomized Double Blind, Placebo Controlled Trial of Rifaximin for Hepatic Encephalopathy Unknown status NCT00281502 Phase 2 Rifaximin (drug)

Search NIH Clinical Center for Hepatic Coma

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Kanamycin Sulfate
Lactulose
NEOMYCIN SO4 PWDR

Cochrane evidence based reviews: hepatic encephalopathy

Genetic Tests for Hepatic Coma

Anatomical Context for Hepatic Coma

MalaCards organs/tissues related to Hepatic Coma:

40
Liver, Brain, Cortex, Kidney, Cerebellum, Heart, Colon

Publications for Hepatic Coma

Articles related to Hepatic Coma:

(show top 50) (show all 9649)
# Title Authors PMID Year
1
Increased levels of pregnenolone and its neuroactive metabolite allopregnanolone in autopsied brain tissue from cirrhotic patients who died in hepatic coma. 61 54
16563564 2006
2
The "peripheral-type" benzodiazepine (omega 3) receptor in hyperammonemic disorders. 61 54
12020611 2002
3
Influence of acute and chronic alcohol intake on the clinical course and outcome in acetaminophen overdose. 54 61
11929388 2002
4
Acute liver failure. 61 54
11132456 1999
5
The effect of flumazenil on subclinical psychometric or neurophysiological alterations in cirrhotic patients: a double-blind placebo-controlled study. 61 54
9347201 1997
6
[Severe Amanita phalloides poisoning in a 7-year-old girl]. 54 61
8348662 1993
7
"Peripheral-type" (mitochondrial) benzodiazepine receptors in hepatic encephalopathy. 54 61
7748297 1993
8
Significance of serum human hepatocyte growth factor levels in patients with hepatic failure. 61 54
1530786 1992
9
Increased densities of peripheral-type benzodiazepine receptors in brain autopsy samples from cirrhotic patients with hepatic encephalopathy. 54 61
2161396 1990
10
Evaluation of cerebral dysfunction in patients with chronic kidney disease using neuropsychometric and neurophysiological tests. 61
33757399 2021
11
Acute hepatic encephalopathy and multiorgan failure in sickle cell disease and COVID-19. 61
33484077 2021
12
A novel method: can stapedial acoustic reflex have a role in the diagnosis of minimal hepatic encephalopathy? 61
32568804 2021
13
Altered intrinsic brain activity in patients with hepatic encephalopathy. 61
33583085 2021
14
Prevention of variceal rebleeding in cirrhotic patients with spontaneous portosystemic shunts: transjugular intrahepatic portosystemic shunt versus endoscopic treatment. 61
33731589 2021
15
Extracorporeal renal and liver support in pediatric acute liver failure. 61
32500250 2021
16
Bifidobacterium longum W11: Uniqueness and individual or combined clinical use in association with rifaximin. 61
33745570 2021
17
Role of serum albumin in hepatic encephalopathy. 61
33797845 2021
18
Efficacy of rifaximin, a poorly absorbed rifamycin antimicrobial agent, for hepatic encephalopathy in Japanese patients. 61
33533150 2021
19
Methylene blue and photobiomodulation recover cognitive impairment in hepatic encephalopathy through different effects on cytochrome c-oxidase. 61
33549685 2021
20
Hepatitis E-Associated Hospitalizations in the United States: 2010-2015 and 2015-2017. 61
33306246 2021
21
The use of automated pupillometry in critically ill cirrhotic patients with hepatic encephalopathy. 61
33388562 2021
22
Carbon-ion radiotherapy subsequent to balloon-occluded retrograde transvenous obliteration for hepatocellular carcinoma with hepatic encephalopathy: a multidisciplinary approach. 61
33811604 2021
23
Relevance of Spontaneous Portosystemic Shunts Detected with CT in Patients with Cirrhosis. 61
33529134 2021
24
Two cases of liver cirrhosis with hyperammonemic encephalopathy caused by urease-producing bacteria in the urinary tract. 61
33400189 2021
25
Potassium deficiency decreases the capacity for urea synthesis and markedly increases ammonia in rats. 61
33404376 2021
26
Liver Transplant Is Associated with Sustained Improvement in Tandem Gait and Risk of Falls. 61
32323075 2021
27
Albumin administration in patients with decompensated liver cirrhosis: a meta-analytic update. 61
32976190 2021
28
Socioeconomic Status is Associated with the Risk of Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation. 61
33663923 2021
29
Osmotic Demyelination Syndrome in Hospitalized Patients With Cirrhosis: Analysis of the National Inpatient Sample (NIS). 61
33731600 2021
30
The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. 61
33301825 2021
31
Systemic Artery Vasoconstrictor Therapy in Fontan Patients with High Cardiac Output-Heart Failure: A Single-Center Experience. 61
33416919 2021
32
Efficacy of TIPS Reduction for Refractory Hepatic Encephalopathy, Right Heart Failure, and Liver Dysfunction. 61
33703927 2021
33
The combination of Child-Pugh score and quantitative CT-based spleen volume could predict the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation. 61
33660042 2021
34
Hepatic Encephalopathy due to Intrahepatic Portosystemic Shunt via Right Adrenal Vein in a Non-Cirrhotic Patient. 61
33288351 2021
35
Nitazoxanide versus Rifaximin in Preventing the Recurrence of Hepatic Encephalopathy: A Randomized Double Blind Controlled Trial. 61
33768619 2021
36
Insight Into The Acute hepatitis A Outbreak In Indiana. 61
33763937 2021
37
CLINICAL CHARACTERISTICS OF ENDOCRINOPATHIES IN CHINESE PATIENTS WITH HEREDITARY HAEMOCHROMATOSIS. 61
33738915 2021
38
The critical role of hippocampal dopamine in the pathogenesis of hepatic encephalopathy. 61
33453721 2021
39
Identification of minimal hepatic encephalopathy based on dynamic functional connectivity. 61
33755921 2021
40
Thioacetamide-induced acute hepatic encephalopathy: central vs peripheral effect of Allicin. 61
33765229 2021
41
Simultaneous bilateral dual mobility total hip arthroplasty dislocation in a patient with hepatic encephalopathy: A case report. 61
33662911 2021
42
Babao Dan improves neurocognitive function by inhibiting inflammation in clinical minimal hepatic encephalopathy. 61
33383371 2021
43
Enhanced Meningeal Lymphatic Drainage Ameliorates Neuroinflammation and Hepatic Encephalopathy in Cirrhotic Rats. 61
33227282 2021
44
Identifying Patients With Hepatic Encephalopathy Using Administrative Data in the ICD-10 Era. 61
31887447 2021
45
Rate, reasons, predictors, and burden of readmissions after transjugular intrahepatic portosystemic shunt placement. 61
32710679 2021
46
Prognosis of patients undergoing salvage TIPS is still poor in the preemptive TIPS era. 61
33667917 2021
47
Effects of transjugular intrahepatic portosystemic shunt using the Viatorr stent on hepatic reserve function in patients with cirrhosis. 61
33728297 2021
48
A Nationwide Analysis of Budd-Chiari Syndrome in the United States. 61
33746442 2021
49
Life Expectancy After Liver Transplantation for Hepatocellular Carcinoma With Cirrhosis. 61
33686888 2021
50
Transjugular intrahepatic portosystemic shunt versus endoscopic therapy for prevention of variceal rebleeding in patients with hepatocellular carcinoma meeting the Milan criteria. 61
32398493 2021

Variations for Hepatic Coma

Expression for Hepatic Coma

Search GEO for disease gene expression data for Hepatic Coma.

Pathways for Hepatic Coma

GO Terms for Hepatic Coma

Cellular components related to Hepatic Coma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 SERPINC1 GPT F3 F2 ALB AFP
2 extracellular exosome GO:0070062 9.5 TSPO SERPINC1 GPT GOT1 F2 DBI
3 blood microparticle GO:0072562 9.33 SERPINC1 F2 ALB
4 endoplasmic reticulum lumen GO:0005788 9.02 SERPINC1 F2 DBI ALB AFP

Biological processes related to Hepatic Coma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.5 SERPINC1 F3 F2
2 positive regulation of reactive oxygen species metabolic process GO:2000379 9.37 TSPO F2
3 transport GO:0006810 9.26 ALB AFP
4 cellular protein metabolic process GO:0044267 9.26 SERPINC1 F2 ALB AFP
5 regulation of blood coagulation GO:0030193 9.16 SERPINC1 F2
6 hemostasis GO:0007599 8.8 SERPINC1 F3 F2

Molecular functions related to Hepatic Coma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fatty acid binding GO:0005504 9.16 ALB AFP
2 transaminase activity GO:0008483 8.96 GPT GOT1
3 pyridoxal phosphate binding GO:0030170 8.8 GPT GOT1 ALB

Sources for Hepatic Coma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....